Standard protocol: drop back to the previous dose for an additional four weeks, then re-attempt escalation
TRIUMPH-3: Weight management in people with cardiovascular disease Additional TRIUMPH Trials: Type 2 diabetes management Chronic low back pain Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH/NAFLD) Cardiovascular and renal outcomes The TRIUMPH program has enrolled more than 5,800 participants total, making it one of the largest Phase 3 programs for an obesity medication in history
Its more accurate to say that semaglutide can put MASH into remission, Barritt says
Mitochondrial p53 is apparently linked to intrinsic apoptosis signaling, so this relocalization is posited to increase susceptibility to apoptosis specifically in senescent cells
-Acts as a protective layer to resist UV damage and the destruction of collagen, keeping skin elasticity, prevents sun pigmentation, wrinkles, and premature aging